Clinical Trial DRUG CNDO109-001
- A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients with High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
- Principal Investigator
- Olga Frankfurt
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.DRUG CNDO109-001
- The primary objective of this study is to define the maximum tolerated dose (MTD), or the maximum tested dose of CNDO-109-Activated Allogeneic Natural Killer cells infused after preparative chemotherapy.
- This study is being done with patients who have acute myeloid leukemia (AML), are in a first complete remission and are considered to be at high risk for the AML to become active again. This is a research study of an experimental study drug, CNDO-109 Activated Allogeneic Natural Killer Cells (NK Cells). “Experimental” means that the study drug is currently being tested and is not approved for sale in the United States by the Food and Drug Administration (FDA). This study is being done to evaluate CNDO-109 Activated Allogeneic Natural Killer Cells (NK Cells) and how patients with acute myeloid leukemia (AML) respond when given this therapy. In this study, White Blood Cells are removed from a healthy donor that is a blood relative (mother, father, sister, brother, child, niece or nephew). Natural Killer cells are part of the white blood cells that are removed from the healthy donor. The Natural Killer cells are separated from the white blood cells and mixed with CNDO-109 Lysate (activated). NK cells are a type of blood cell in the immune system that attack cancer cells.
Some of the eligibility criteria include:
- Participants must have AML that is in a first complete remission.
- Participants must either not be a good candidate for, or have refuse, a stem cell transplant.
- Participants must be 18 or older.
- Participants must have an available NK cell donor.
- Description of Treatment
- Participants in this study will start their treatment with a 5 days of pre-study drug prep therapy, including the standard chemotherapy drugs fludarabine and cyclophosphamide. This regimen happens on days -6 through -2. On day 0, eligible participants receive a 10 minute infusion of the study drug.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Olga Frankfurt
- CALGB 10701: A Phase II Study of Dasatinib (Sprycel®) (Ind #73969, Nsc #732517) as Primary Therapy Followed by Transplantation for Adults = 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG
- An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
- Phase III, Multicenter, Randomized, Trial Of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years Of Age with Untreated High Risk (Secondary) AML
- An Open Label, Multi-Center Imatinib Roll-Over Protocol for Patients who Have Completed a Previous Novartis sponsored Imatinib Study and are Judged by the Investigator to Benefit from Continued Imatinib Treatment
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Relapsed and/or Treatment-Refractory Leukemia
- A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician’s Choice in Patients = 60 Years Old with Relapsed/Refractory Acute Myeloid Leukemia (AML) Who are Ineligible for Intensive Chemotherapy and/or Transplantation
last updated: 31-Oct-14 06:39 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.